Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sylentis SA

Division of PharmaMar SA/Zeltia SA
www.sylentis.com

Latest From Sylentis SA

Mixed Results From ReGenTree's DES Therapy In Second Phase III

ReGenTree has reported mixed results in its second pivotal Phase III trial of RGN-259 indicating that the therapy is most effective in patients with severe dry eye. The results raise some doubts about the treatment’s potential approval for the general dry eye population.

Research & Development Clinical Trials

Pipeline Watch: Top-Line Fremanezumab, Ramucirumab, Bictegravir Results

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deals Shaping The Medical Industry (01/2012)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Yondelis drives Zeltia Group's biopharmaceutical business

Yondelis (trabectedin) again drove the Spanish biotech group Zeltia's first-quarter business and helped the group's EBITDA break even.

Cancer Neurology
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Spain
  • Parent & Subsidiaries
  • PharmaMar SA
  • Senior Management
  • Contact Info
  • Sylentis SA
    Phone: 918047667
    C/Santiago Grisolia 2
    Parque Cientifi
    Tres Cantos, 28760
    Spain
Advertisement
Advertisement
UsernamePublicRestriction

Register